Profile data is unavailable for this security.
About the company
Suven Pharmaceuticals Limited is an India-based company. The Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Specialty Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology, and chemical companies. The Company operates through Manufacturing segment. Its geographical segments include India, the United States, Europe, and Rest of the world. In India, the Company sells bulk drugs and intermediates, fine chemicals & services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In other countries, the Company sells bulk drugs, intermediates, and services. The Company’s subsidiaries are Suven Pharma Inc. and Casper Pharma Private Limited.
- Revenue in INR (TTM)9.34bn
- Net income in INR2.40bn
- Incorporated2018
- Employees1.05k
- LocationSuven Pharmaceuticals LtdSDE Serene ChambersRoad no. 5, Avenue 7, Banjara hillsHYDERABAD 500081IndiaIND
- Phone+91 4 023549414
- Fax+91 4 023541152
- Websitehttps://www.suvenpharm.com/
More ▼
Mergers & acquisitions
| Acquired company | SUVENPHAR:NSI since announced | Transaction value |
|---|---|---|
| Cohance Lifesciences Ltd | 107.57% | 981.19m |
Data delayed at least 15 minutes, as of Nov 01 2024 13:19 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 190.62bn | 940.00 | 198.86 | -- | 171.87 | 13.74 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
| Concord Biotech Ltd | 10.38bn | 3.13bn | 191.48bn | 1.38k | 61.15 | -- | 52.18 | 18.45 | 29.93 | 29.93 | 99.19 | -- | -- | -- | -- | 7,537,496.00 | -- | -- | -- | -- | 77.16 | -- | 30.18 | -- | -- | 115.93 | -- | -- | 19.20 | -- | 28.33 | -- | -- | -- |
| Jubilant Pharmova Ltd | 69.20bn | 5.93bn | 191.94bn | 995.00 | 32.41 | 3.23 | 19.86 | 2.77 | 37.38 | 37.38 | 436.41 | 375.04 | 0.5934 | 1.75 | 8.15 | 69,544,720.00 | 5.05 | 2.96 | 6.01 | 3.55 | 68.50 | 68.47 | 8.51 | 5.13 | 1.20 | 2.51 | 0.342 | 24.73 | 6.70 | -5.95 | 226.43 | -33.08 | 6.48 | 2.13 |
| Alembic Pharmaceuticals Ltd | 63.04bn | 6.30bn | 221.89bn | 14.86k | 35.23 | -- | 24.51 | 3.52 | 32.04 | 32.04 | 320.63 | -- | -- | -- | -- | 4,242,974.00 | -- | 10.72 | -- | 14.25 | 73.10 | 65.98 | 9.99 | 12.47 | -- | 12.52 | -- | 28.29 | 10.19 | 9.62 | 80.07 | 1.05 | -15.59 | 14.87 |
| Pfizer Ltd | 22.38bn | 6.18bn | 233.22bn | 1.72k | 37.75 | 6.22 | 34.36 | 10.42 | 135.06 | 135.06 | 489.19 | 819.90 | 0.5288 | 1.83 | 11.16 | 13,004,360.00 | 14.60 | 14.22 | 17.05 | 17.71 | 65.00 | 61.37 | 27.61 | 24.05 | 4.30 | 46.21 | 0.0267 | 82.67 | -9.55 | 1.05 | -11.64 | 5.14 | 33.35 | 9.24 |
| Natco Pharma Ltd. | 42.21bn | 16.37bn | 251.28bn | 4.02k | 15.35 | -- | 13.78 | 5.95 | 91.37 | 91.37 | 235.68 | -- | -- | -- | -- | 10,510,210.00 | -- | 12.33 | -- | 14.25 | 83.40 | 73.05 | 38.77 | 25.16 | -- | 91.13 | -- | 18.96 | 47.72 | 13.81 | 94.09 | 16.59 | -4.71 | 14.87 |
| Laurus Labs Ltd | 50.53bn | 1.31bn | 264.86bn | 6.01k | 201.92 | 6.40 | 48.58 | 5.24 | 2.43 | 2.43 | 93.70 | 76.70 | 0.602 | 1.18 | 3.06 | 8,412,186.00 | 1.55 | 10.13 | 2.52 | 16.47 | 53.44 | 47.63 | 2.58 | 12.83 | 0.5818 | 1.81 | 0.4023 | 13.00 | -16.55 | 17.07 | -79.68 | 11.36 | 21.68 | 21.67 |
| Gland Pharma Ltd | 58.58bn | 7.22bn | 272.02bn | 4.22k | 37.67 | -- | 24.88 | 4.64 | 43.83 | 43.83 | 355.57 | -- | -- | -- | -- | 13,890,770.00 | -- | 13.23 | -- | 14.56 | 61.00 | 55.58 | 12.33 | 22.92 | -- | 34.66 | -- | 7.26 | 56.29 | 22.61 | -1.10 | 11.32 | 24.02 | -- |
| Emcure Pharmaceuticals Ltd | -100.00bn | -100.00bn | 272.13bn | 11.15k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 7.14 | -- | 13.93 | -- | 59.29 | -- | 7.81 | -- | -- | -- | 0.00 | 11.23 | 7.14 | -6.36 | 21.35 | -5.93 | -- |
| J B Chemicals and Pharmaceuticals Ltd | 35.92bn | 5.87bn | 304.58bn | 5.31k | 53.02 | -- | 41.45 | 8.48 | 36.99 | 36.99 | 226.16 | -- | -- | -- | -- | 6,764,044.00 | -- | 15.77 | -- | 18.89 | 66.27 | 61.18 | 16.34 | 16.06 | -- | 21.04 | -- | 33.08 | 10.63 | 16.22 | 34.84 | 23.36 | 40.15 | 37.42 |
| Suven Pharmaceuticals Ltd | 9.34bn | 2.40bn | 334.35bn | 1.05k | 138.89 | -- | 112.99 | 35.78 | 9.46 | 9.46 | 36.75 | -- | -- | -- | -- | 8,883,019.00 | -- | 23.17 | -- | 26.20 | 56.59 | 58.85 | 25.73 | 33.21 | -- | 33.74 | -- | 18.63 | -21.56 | 22.71 | -26.99 | 22.41 | -1.83 | -- |
| Piramal Pharma Ltd | 87.04bn | 453.30m | 354.33bn | 6.72k | 787.95 | 4.48 | 44.04 | 4.07 | 0.3407 | 0.3407 | 66.36 | 59.91 | 0.5799 | 1.40 | 4.88 | 12,954,040.00 | 0.302 | -- | 0.428 | -- | 63.69 | -- | 0.5208 | -- | 0.5603 | 7.49 | 0.3771 | -- | 15.39 | -- | 109.56 | -- | -- | -- |
| Ajanta Pharma Ltd | 44.91bn | 8.75bn | 382.82bn | 7.84k | 44.06 | 10.41 | 37.83 | 8.52 | 69.55 | 69.55 | 356.94 | 294.36 | 0.9738 | 1.33 | 4.16 | 5,725,128.00 | 18.97 | 16.61 | 23.29 | 20.47 | 75.77 | 73.22 | 19.48 | 19.31 | 2.13 | 49.88 | 0.0088 | 31.20 | 12.45 | 15.41 | 38.81 | 16.10 | -14.97 | 10.76 |
| IPCA Laboratories Ltd | 82.12bn | 5.77bn | 403.09bn | 17.34k | 69.88 | -- | 42.48 | 4.91 | 22.74 | 22.74 | 323.71 | -- | -- | -- | -- | 4,737,502.00 | -- | 10.33 | -- | 13.52 | 67.08 | 59.16 | 6.84 | 12.25 | -- | 15.41 | -- | 12.86 | 23.39 | 15.35 | 16.13 | 4.24 | 17.90 | 21.67 |
| GlaxoSmithKline Pharmaceuticals Limited | 35.60bn | 6.75bn | 459.47bn | 3.21k | 68.49 | 27.47 | 61.80 | 12.90 | 39.60 | 39.60 | 209.31 | 98.74 | 1.01 | 2.59 | 14.85 | 11,088,370.00 | 19.24 | 11.01 | 36.09 | 17.88 | 61.70 | 55.77 | 18.96 | 12.25 | 1.38 | 554.80 | 0.0088 | 192.07 | 6.21 | 2.00 | -2.91 | 5.78 | -36.02 | 9.86 |
| Glenmark Pharmaceuticals Ltd | 120.21bn | -15.73bn | 478.18bn | 14.99k | -- | -- | -- | 3.98 | -55.78 | -46.50 | 425.96 | -- | -- | -- | -- | 8,020,026.00 | -- | 1.02 | -- | 1.43 | 63.93 | 59.47 | -12.71 | 1.43 | -- | 1.78 | -- | 56.98 | 1.98 | 3.67 | -1,018.93 | -- | -5.89 | 4.56 |
Data as of Nov 01 2024. Currency figures normalised to Suven Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
16.81%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| DSP Asset Managers Pvt. Ltd.as of 30 Sep 2024 | 13.61m | 5.35% |
| UTI Asset Management Co. Ltd. (Investment Management)as of 30 Sep 2024 | 5.44m | 2.14% |
| SBI Life Insurance Co. Ltd. (Investment Portfolio)as of 31 Aug 2024 | 4.53m | 1.78% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 3.89m | 1.53% |
| Goldman Sachs Asset Management LPas of 30 Aug 2024 | 3.03m | 1.19% |
| HSBC Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 2.87m | 1.13% |
| Tata Asset Management Pvt Ltd.as of 30 Sep 2024 | 2.61m | 1.03% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 2.56m | 1.01% |
| Invesco Asset Management (India) Pvt Ltd.as of 30 Sep 2024 | 2.54m | 1.00% |
| Axis Asset Management Co. Ltd.as of 30 Sep 2024 | 1.72m | 0.68% |
More ▼
Data from 30 Jun 2024 - 15 Oct 2024Source: FactSet Research Systems Inc.
